Oncotarget is an online medical journal that was introduced in 2010. The minds behind the online medical journal are Mikhail Blagosklonny and Andrei Gurkov. They are working with the Roswell Park Cancer Institute, and the idea to create an online medical journal stemmed from their first-hand experiences about scientists who are having a hard time communicating with their colleagues. They wanted to create a venue where all scientists who are working on cancer can talk and share knowledge. They formed Oncotarget with the objective that it will be creating a bridge for the scientists, and since its inception in 2010, the scientific community had been using it indefinitely for their research. Check the journal at SCImago Journal & Country Rank.
— Oncotarget (@OncotargetJrnl) December 12, 2017
Initially designed to release only one article per week, Oncotarget is now releasing two articles per week. Each article talks about the advancement of science in treating cancer, or any other cancer-related topics. Oncotarget is also known as the most popular peer-reviewed online medical journal. Mikhail Blagosklonny and Andrei Gurkov explained that when scientists are submitting their works, a panel of scientists will be reviewing the work to make sure that all of the information is accurate and up to date. Any revisions will result in the article to be sent back to the scientist for them to reread and rewrite. The public gave Oncotarget a positive reception, stating that the availability of scientific articles to the people will result in a more knowledgeable population. Oncotarget can be accessed by anyone on the planet, and all of the articles are uploaded online. Visit Oncotarget’s profile page at facebook.com
Aside from monitoring the articles being submitted to the online medical journal, Oncotarget is also making sure that the information posted is being shared with the public. This year, four scientists were sent by Oncotarget to attend a conference in Singapore, and they will be talking about the latest advancements in fighting the disease. Oncotarget wanted to assure the public that they are doing everything to fight the disease.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/